UB Paderborn / Katalog / Suche / in CDI

Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex

The Journal of pharmacology and experimental therapeutics, 2011-09, Vol.338 (3), p.803

2011

Volltextzugriff (PDF)

The inactivation of human CYP2E1 by phenethyl isothiocyanate, a naturally occurring chemopreventive agent, and its oxidative bioactivation

Drug metabolism and disposition, 2013-04, Vol.41 (4), p.858

2013

Volltextzugriff (PDF)

Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts

Drug metabolism and disposition, 2012-12, Vol.40 (12), p.2256

2012

Volltextzugriff (PDF)

Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases

Drug metabolism and disposition, 2004-06, Vol.32 (6), p.587

2004

Volltextzugriff (PDF)

The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6

The Journal of pharmacology and experimental therapeutics, 2008-11, Vol.327 (2), p.538

2008

Volltextzugriff (PDF)

Differential inhibition of cytochromes P450 3A4 and 3A5 by the newly synthesized coumarin derivatives 7-coumarin propargyl ether and 7-(4-trifluoromethyl)coumarin propargyl ether

Drug metabolism and disposition, 2008-11, Vol.36 (11), p.2234

2008

Volltextzugriff (PDF)

The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation

Drug metabolism and disposition, 2005-06, Vol.33 (6), p.795

2005

Volltextzugriff (PDF)

Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6

The Journal of pharmacology and experimental therapeutics, 2002-06, Vol.301 (3), p.945

2002

Volltextzugriff (PDF)

Bioactivation of the cancer chemopreventive agent tamoxifen to quinone methides by cytochrome P4502B6 and identification of the modified residue on the apoprotein

Drug metabolism and disposition, 2012-12, Vol.40 (12), p.2280

2012

Volltextzugriff (PDF)

Identification of amino acid residues involved in the inactivation of cytochrome P450 2B1 by two acetylenic compounds: the role of three residues in nonsubstrate recognition Sites

The Journal of pharmacology and experimental therapeutics, 2004-10, Vol.311 (1), p.71

2004

Volltextzugriff (PDF)

Synthesis of substituted phenyl diaziridines and characterization as mechanism-based inactivators of human cytochrome P450 2B6

Drug metabolism and disposition, 2006-11, Vol.34 (11), p.1849

2006

Volltextzugriff (PDF)

Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6

Drug metabolism and disposition, 2011-05, Vol.39 (5), p.782

2011

Volltextzugriff (PDF)

Structure-activity relationship and elucidation of the determinant factor(s) responsible for the mechanism-based inactivation of cytochrome P450 2B6 by substituted phenyl diaziridines

Drug metabolism and disposition, 2006-12, Vol.34 (12), p.2102

2006

Volltextzugriff (PDF)

Quantitation of UGT1A1 in human liver microsomes using stable isotope-labelled peptides and mass spectrometry based proteomic approaches

Xenobiotica, 2013-04, Vol.43 (4), p.336-345

2013

Volltextzugriff (PDF)

Metabolism of Cyclophosphamide by the Human Cytochrome P450 2B6 Polymorphic Variants

The FASEB journal, 2012-04, Vol.26 (S1)

2012

Volltextzugriff (PDF)

The endocannabinoid anandamide is a substrate of cytochrome P450 2D6

The FASEB journal, 2008-03, Vol.22 (S1)

2008

Volltextzugriff (PDF)

Modification of Serine 360 by a Reactive Intermediate of 17-a-Ethynylestradiol Results in Mechanism-Based Inactivation of Cytochrome P450s 2B1 and 2B6

Chemical research in toxicology, 2008-10, Vol.21 (10), p.1956-1963

2008

Volltextzugriff (PDF)

Modification of Serine 360 by a Reactive Intermediate of 17-α-Ethynylestradiol Results in Mechanism-Based Inactivation of Cytochrome P450s 2B1 and 2B6

Chemical research in toxicology, 2008-10, Vol.21 (10), p.1956-1963

2008

Volltextzugriff (PDF)

Modification of Serine 360 by a Reactive Intermediate of 17-α-Ethynylestradiol Leads to Mechanism-based Inactivation of Cytochrome P450s 2B1 and 2B6

Chemical research in toxicology, 2008-08, Vol.21 (10), p.1956-1963

2008

Volltextzugriff (PDF)

Roles of the threonine 407, aspartic acid 417, and threonine 419 residues in P450 2B1 in metabolism

Biochemical and biophysical research communications, 2005-12, Vol.338 (1), p.386-393

2005

Volltextzugriff (PDF)

Feasibility of Allogeneic Hematopoietic Stem Cell Transplantation for Autoimmune Disease: Position Statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute–Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005

Biology of blood and marrow transplantation, 2005-11, Vol.11 (11), p.862-870

2005

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex

The inactivation of human CYP2E1 by phenethyl isothiocyanate, a naturally occurring chemopreventive agent, and its oxidative bioactivation

Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts

Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases

The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6

Differential inhibition of cytochromes P450 3A4 and 3A5 by the newly synthesized coumarin derivatives 7-coumarin propargyl ether and 7-(4-trifluoromethyl)coumarin propargyl ether

The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation

Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6

Bioactivation of the cancer chemopreventive agent tamoxifen to quinone methides by cytochrome P4502B6 and identification of the modified residue on the apoprotein

Identification of amino acid residues involved in the inactivation of cytochrome P450 2B1 by two acetylenic compounds: the role of three residues in nonsubstrate recognition Sites

Synthesis of substituted phenyl diaziridines and characterization as mechanism-based inactivators of human cytochrome P450 2B6

Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6

Structure-activity relationship and elucidation of the determinant factor(s) responsible for the mechanism-based inactivation of cytochrome P450 2B6 by substituted phenyl diaziridines

Quantitation of UGT1A1 in human liver microsomes using stable isotope-labelled peptides and mass spectrometry based proteomic approaches

Metabolism of Cyclophosphamide by the Human Cytochrome P450 2B6 Polymorphic Variants

The endocannabinoid anandamide is a substrate of cytochrome P450 2D6

Modification of Serine 360 by a Reactive Intermediate of 17-a-Ethynylestradiol Results in Mechanism-Based Inactivation of Cytochrome P450s 2B1 and 2B6

Modification of Serine 360 by a Reactive Intermediate of 17-α-Ethynylestradiol Results in Mechanism-Based Inactivation of Cytochrome P450s 2B1 and 2B6

Modification of Serine 360 by a Reactive Intermediate of 17-α-Ethynylestradiol Leads to Mechanism-based Inactivation of Cytochrome P450s 2B1 and 2B6

Roles of the threonine 407, aspartic acid 417, and threonine 419 residues in P450 2B1 in metabolism

Feasibility of Allogeneic Hematopoietic Stem Cell Transplantation for Autoimmune Disease: Position Statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute–Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005

Suchergebnisse filtern